FIELD: medicine, pharmacy. SUBSTANCE: invention relates to erythropoietin liposomal dispersion. Liposome-base composition contains: (a) effective amount of erythropoietin; (b) lipid phase comprising: (i) lecithin or hydrogenated lecithin; (ii) optionally charged electropositive or electronegative lipid compound; and (iii) cholesterol or its derivative taken among cholesterol esters, polyethylene glycol derivatives of cholesterol (PEG-cholesterols) and organic acid derivatives of cholesterols; and (c) phosphate buffer. Invention provides preparing the liposome-base composition for parenteral administration that excludes using human serum albumin and composition shows the excellent stability. EFFECT: valuable medicinal and pharmaceutical properties of dispersion. 14 cl, 2 tbl
Title | Year | Author | Number |
---|---|---|---|
LIPOSOMAL COMPOSITION WITH PACLITAXEL FOR TREATING CANCER AND METHOD FOR ITS OBTAINING | 2001 |
|
RU2264807C2 |
STABLE LIPOSOMAL COMPOSITIONS | 2004 |
|
RU2369384C2 |
LIPOSOMAL COMPOSITION AND METHOD OF ITS PREPARATION | 2012 |
|
RU2514000C1 |
LIPOSOMAL AGENT BASED ON UBIQUINOL AND PREPARATION METHOD THEREOF | 2015 |
|
RU2605616C1 |
LIPOSOMAL COMPOSITION AND METHOD FOR PRODUCTION THEREOF | 2012 |
|
RU2516893C1 |
METHOD OF LYOPHILIZED LIPOSOME PREPARING | 1997 |
|
RU2144352C1 |
IRINOTECAN LIPOSOMES OR ITS SALTS, METHOD FOR PREPARING THEM | 2009 |
|
RU2526114C2 |
LIPOSOMAL DRUG FOR USE IN THE TREATMENT OF MALIGNANT NEOPLASM | 2017 |
|
RU2756755C2 |
LIPOSOMAL COMPOSITION | 2010 |
|
RU2476216C1 |
DRIED RECONSTITUTED VESICLES FOR PHARMACEUTICAL APPLICATION | 2007 |
|
RU2443412C2 |
Authors
Dates
2003-12-20—Published
1999-02-12—Filed